Tildrakizumab-asmn: What's in a Name?

Am J Clin Dermatol. 2018 Jun;19(3):291-292. doi: 10.1007/s40257-018-0357-6.

Authors

Eric J Yang^{1

2}, Kristen M Beck³, Wilson Liao³

Affiliations

¹ Department of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA, 94118, USA. [email protected].
² Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA. [email protected].
³ Department of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA, 94118, USA.

PMID: 29687361
DOI: 10.1007/s40257-018-0357-6

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Biosimilar Pharmaceuticals / standards*
Biosimilar Pharmaceuticals / therapeutic use
Humans
Psoriasis / drug therapy
Terminology as Topic*
United States
United States Food and Drug Administration / standards*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biosimilar Pharmaceuticals
tildrakizumab